Claire Roddie, PhD, MBChB, on B-ALL: Safety and Efficacy Data of Obecabtagene Autoleucel

2023 ASCO Annual Meeting


Claire Roddie, PhD, MBChB, of University College London, discusses results of the FELIX study, which showed that the second-generation chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel is safe for adults with relapsed or refractory B-cell acute lymphoblastic leukemia, even those with a high burden of disease. This agent yielded high rates of complete response and ongoing CAR T-cell persistence in most patients whose disease responded (Abstract 7000).


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Claire Roddie: I'm here today to talk about the FELIX study, that's the study of obe-cel in adult acute lymphoblastic leukemia. Essentially, obe-cel is a novel CD-19 CAR with a fast off rate CD-19 binding domain that confers less toxicity and promotes CAR T-cell persistence. We've tested it with the center I work at in London in a phase one study in 20 patients with acute lymphoblastic leukemia, and the results were so promising that it sparked this phase two endeavor, this FELIX study, which is a global study that's been sponsored by Autolus Therapeutics. To describe this study, essentially, it's an autologous CD-19 CAR T product for patients. They're leukapheresed, they then received bridging chemotherapy, fludarabine cyclophosphamide, and then they receive split dose CAR T-cell infusion over day one and day 10. Essentially, that's again to mitigate for immunotoxicity and they also have their initial dose titrated to disease burden on the prelim food depletion bone marrow.These are all safety features built into the study design. Essentially, on this study we infused 94 patients and given the split dosing, actually on this study, 94% of patients received both doses, which was a really good outcome. The patient population we were dealing with was particularly high risk, so there were a lot of patients with high burden disease. There was a significant portion with extramedullary disease, which we recognized to be a particularly high risk population, so we were dealing with a difficult patient cohort here. But despite that and despite the circulating disease and high burden disease, the manufacture process was extremely successful. 94% of our patients who were leukapheresed had a product released for infusion, which was a great outcome. The event release time on this study was 21 days median. Now in terms of outcomes for these patients, despite the heavy disease burden and the poor risk cohort, actually we saw complete responses in 76% of patients. What's more, those responses were deep responses, so MRD negative in 97% of patients, which is obviously excellent for us as physicians and a lot of those responses were durable, so 61% of the responses were ongoing at that median of 9.5 months. Again, they continued under close observation, that group. Now, this is really probably quite key, the toxicity profile. CAR T-cell therapy is sometimes not very well tolerated by patients, particularly older patients and patients with comorbidities. But this product, this obe-cel cell is unique in that regard. Also, because we're very minimal grade three immunotoxicity on this study. Only 3% of patients experienced grade three CRS and only 7% experienced grade three ICANS, so in a sense this is very different to what's been described with other CAR T-cell therapies for adult acute lymphoblastic leukemia. It makes it a much more appealing potential therapy for these older and more challenging patients. When we look in the blood of these patients, and this is another important feature to recognize, is that at last followup, we're seeing the CAR T cells persisting in these patients right the way up until that median follow-up of 9.5 months. This product continues to proliferate within the patient bloodstream in an ongoing way, continuing to survey the body looking for disease and in an ongoing way immunologically rejecting the leukemia in the event of relapse. That's a very encouraging thing for us as well to see that persistence and we hope that that will lead to durable responses in due course. But that's where we've got to so far with the study and we look forward to updating with more followup as the months go by.

Related Videos

Skin Cancer

Allison Betof Warner, MD, PhD, and Adnan Khattak, PhD, MBBS, on High-Risk Resected Melanoma: Survival Results With mRNA-4157 and Pembrolizumab in KEYNOTE-942

Allison Betof Warner, MD, PhD, of Stanford University Medical Center, and Adnan Khattak, MBBS, FRACP, PhD, of Australia’s Hollywood Private Hospital & Edith Cowan University, discuss the use of the mRNA-4157 vaccine in combination with pembrolizumab as adjuvant therapy for resected high-risk melanoma, which prolonged distant metastasis–free survival compared with pembrolizumab alone. These results provide further evidence that a personalized neoantigen approach is potentially beneficial (Abstract LBA9503).

Bladder Cancer

Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib vs Chemotherapy From the THOR Study

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings showing that for patients with advanced or metastatic urothelial carcinoma and FGFR alteration who already had been treated with a PD-(L)1 inhibitor, erdafitinib significantly improved overall and progression-free survival, as well as overall response rate, compared with investigator’s choice of chemotherapy (LBA4619).

Prostate Cancer

Alberto Bossi, MD, on Prostate Cancer: PEACE-1 Trial Findings on Radiotherapy Plus Systemic Treatment

Alberto Bossi, MD, of Institut Gustave Roussy, discusses phase III findings showing that combining prostate radiotherapy with systemic treatment did not improve overall survival in men with de novo metastatic castration-sensitive prostate cancer and low metastatic burden. However, best outcomes (radiographic progression–free-survival and overall survival) were observed in men receiving the standard of care plus abiraterone acetate plus prednisone with radiotherapy (Abstract LBA5000).

Lung Cancer

Narjust Florez, MD, and Ticiana Leal, MD, on Metastatic NSCLC: Tumor Treating Fields Therapy After Platinum Resistance

Narjust Florez, MD, of Dana-Farber Cancer Institute, and Ticiana Leal, MD, of Winship Cancer Institute of Emory University, discuss the use of tumor treating fields therapy, in which electric fields disrupt processes critical for cancer cell viability. Already approved by the FDA to treat glioblastoma and mesothelioma, the treatment has extended overall survival in this phase III study of patients with metastatic non–small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, without exacerbating systemic toxicities (Abstract LBA9005).


Eunice S. Wang, MD, and Gregory Roloff, MD, on B-ALL: Outcomes With Brexucabtagene Autoleucel in Adult Patients

Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, and Gregory Roloff, MD, of the University of Chicago, discuss data that are the first to demonstrate post–FDA approval efficacy and toxicity rates of brexucabtagene autoleucel in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Although the data may confirm high response rates associated with this agent, they also highlight the need for interventions to reduce associated toxicities (Abstract 7001).